Nature Family: Choosing the Right Journal

The Nature Portfolio is the largest collection of high-impact journals in science, spanning from the flagship Nature (IF 48.5) through specialist titles to the broad-scope Nature Communications (IF 15.7). For researchers, this creates both an opportunity and a confusion problem: with dozens of Nature-branded journals, where does your paper actually belong?

The answer matters because the Nature transfer system actively moves papers between journals. A paper submitted to Nature might end up in Nature Medicine, Nature Genetics, or Nature Communications - and that's not necessarily a bad outcome. Understanding the hierarchy helps you submit strategically rather than blindly aiming at the top and hoping for the best.

This guide covers seven of the most important Nature Portfolio journals and explains how they relate to each other: their scopes, editorial bars, and the transfer cascade that connects them.

Head-to-Head Comparison

The Hierarchy: Understanding Where Each Journal Sits

Nature (IF 48.5) is the flagship - broad-scope, field-changing, and ruthlessly selective. A Nature paper must interest scientists across all disciplines. The question is always "will this be discussed in departments far outside the author's field?"

Nature Medicine (IF 50.0) actually outranks Nature in impact factor. It occupies the translational sweet spot between Cell (pure mechanism) and NEJM (pure clinical practice). The editorial question is: does this connect basic discovery to human health? Mouse-only studies without human data rarely make it anymore. First-in-human studies, even Phase 1, can be appropriate - unlike NEJM, which wants Phase 3.

Nature Biotechnology (IF 41.7) publishes technology that changes how biology gets done. CRISPR tools, sequencing platforms, computational methods. The question isn't "is this good biology?" but "will this tool be in every lab in five years?" With a 4-day median to first decision, it's one of the fastest journals at any tier.

Nature Methods (IF 32.1) is the life science methods specialist. The distinction from Nature Biotechnology: Methods publishes tools for working scientists' specific experimental workflows; Biotechnology publishes platform technologies with broader industrial and research implications. Fiji, Bowtie 2, and STAR aligner were published here. The 5-year IF (51.7) tells the real story - methods papers accumulate citations for years.

Nature Genetics (IF 29.0) is where the big genetic studies land - major GWAS, UK Biobank analyses, large sequencing efforts. Scale and power are expected. Association without functional follow-up faces increasing skepticism; diverse (non-European-only) populations are actively valued.

Nature Immunology (IF 27.6) publishes fundamental immunology with translational relevance. It outranks its primary competitor Immunity (26.3) and is distinguished by all-professional editors with 5-day median decisions. Double-blind review is available as an opt-in.

Nature Communications (IF 15.7) is the broad-scope open-access workhorse. It publishes significant research across all sciences - solid work that advances understanding without requiring Nature-level "transformation." At ~20% acceptance, it's substantially more accessible than the specialist journals, and many papers arrive via transfer from Nature or Nature family journals.

The Transfer Cascade

The Nature Portfolio transfer system is one of the most active in publishing. When a paper is rejected from one journal, editors can suggest transfer to another with reviewer reports intact. The receiving journal can use those reviews, potentially shortening the process by months.

The most common cascades:

Nature → Nature Medicine / Nature Genetics / Nature Biotechnology / other specialist → Nature Communications → Communications Biology / Scientific Reports. A paper too specialized for Nature might be perfect for a specialist title. If still not quite right, Nature Communications catches solid science that doesn't need specialist-level significance.

Nature Immunology → Nature Communications → Communications Biology. Immunology papers too narrow for Nat Immunol can find homes at Nature Communications.

Nature Methods → Nature Communications → Communications Biology. Methods papers that lack broad enough applicability for Nature Methods may work at Nat Comms.

Key points about transfers: (1) Taking a transfer isn't a rejection - it's a journal fit judgment. (2) Transferred papers may be accepted at the new journal without additional external review if the existing reviews are strong. (3) Transfers save months compared to starting fresh. (4) The reputation of your paper is determined by its content, not whether it arrived by transfer.

Strategic insight: if you're aiming for Nature but realistic about your chances, including a note in your cover letter about which Nature family journals you'd consider can help editors route your paper efficiently.

When to Aim High vs Be Realistic

Every Nature submission has an opportunity cost. While your paper sits in one journal's queue, it can't be at another. With desk rejection rates of 60–85% across the family, most submissions don't make it past the first gate. This makes strategic submission - rather than always-aim-for-Nature - the smarter approach.

Aim for Nature when: your finding genuinely has cross-disciplinary significance. A biologist, physicist, and chemist would all find it interesting. The "cocktail party test" - can you explain why this matters to a smart non-scientist in one minute? - should clearly pass.

Aim for the specialist journal when: your finding is the strongest paper in your specific field this year, but its significance is primarily within that field. A landmark immunology finding goes to Nature Immunology or Immunity. A major genetics study goes to Nature Genetics. These journals carry enormous weight within their fields, and being the top paper in Nature Immunology is often more impactful for your career than being a mid-tier paper that squeaked into Nature.

Go directly to Nature Communications when: your paper is technically strong and represents a meaningful advance, but you know it doesn't have the "wow factor" for the specialist titles. Nat Comms is a respected, well-cited venue, and at ~20% acceptance, it's still selective. Don't treat it as a last resort - treat it as a strategic first choice.

The biggest mistake researchers make: submitting to Nature by default, then serially cascading down through specialist journals over 6–12 months. If you're honest about where your paper sits, you can often reach publication months faster by targeting the right journal first.

All Professional Editors: What This Means for You

Every Nature Portfolio journal uses full-time professional editors with PhDs - no external editorial boards making accept/reject decisions. This creates a distinctive editorial culture:

Consistency: The same small team handles all papers in a subject area. Decisions are more predictable than at journals with rotating academic editors who bring personal biases.

Speed: Professional editors can move quickly because reviewing papers is their full-time job. This explains the fast desk decisions (4–7 days at several Nature journals).

Breadth: Editors handle papers across multiple subfields, so they evaluate significance for a broad audience. This is why "narrow interest" is a top rejection reason - editors who see immunology, cancer, and metabolism papers daily can quickly assess whether your paper has cross-subfield appeal.

No lobbying: You can't call a board member to advocate for your paper. The paper must speak for itself through the cover letter and abstract. This makes the presubmission inquiry - available at most Nature journals - especially valuable. A 1-week investment in a presubmission inquiry can save months.